Product
Supplier
Encyclopedia
Inquiry

EN

Home > Chemial News > Pharma News > Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody

Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody

worldpharmnews 2020-10-21

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio , a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease.


Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020. Full results are available here. MRT5500 is being developed under a collaboration agreement between Sanofi Pasteur and Translate Bio.

Share to:
Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Suggestions
Email:
Message:
Send Message